Anaptysbio, Inc (ANAB): who owns it and who trades it
As of Nov 16, 2026, ANAB insiders reported 42 open-market sales worth $9.8M and no purchases in the last 12 months, with 37% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Faga (CEO), with $2.8M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Anaptysbio
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANAB
211 funds and institutions reported ANAB shares worth $2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is EcoR1 Capital, LLC with 27.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.88M | 27.08% | $532M | No change |
| BlackRock, Inc. | 1.84M | 6.34% | $124M | +10% |
| Tang Capital Management LLC | 1.33M | 4.57% | $89.8M | No change |
| State Street Corp | 1.29M | 4.42% | $86.8M | +30% |
| Vanguard Capital Management LLC | 906,233 | 3.11% | $61.2M | +6% |
| Affinity Asset Advisors, LLC | 826,109 | 2.84% | $55.8M | -12% |
| Sanofi | 821,917 | 2.82% | $55.5M | No change |
| Millennium Management LLC | 807,316 | 2.77% | $54.5M | +70% |
| Woodline Partners LP | 717,014 | 2.46% | $48.4M | +108% |
| 683 Capital Management, LLC | 660,000 | 2.27% | $44.6M | +6% |
| Geode Capital Management, LLC | 637,873 | 2.19% | $43.1M | +23% |
| Palo Alto Investors LP | 603,489 | 2.07% | $40.7M | -5% |
| Goldman Sachs Group Inc | 584,070 | 2.01% | $39.4M | +76% |
| First Light Asset Management, LLC | 582,004 | 2.00% | $39.3M | +3% |
| D. E. Shaw & Co., Inc. | 539,666 | 1.85% | $36.4M | -7% |
| Vanguard Portfolio Management LLC | 527,858 | 1.81% | $35.6M | +2% |
| Apis Capital Advisors, LLC | 497,000 | 1.71% | $33.5M | +109% |
| Sofinnova Investments, Inc. | 493,536 | 1.70% | $33.3M | +99% |
| Arrowstreet Capital, Limited Partnership | 488,651 | 1.68% | $33M | -1% |
| Nuveen, LLC | 420,664 | 1.45% | $28.4M | +33% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANAB insiders reported $0 of open-market purchases and $9.8M of sales. 37% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Hollings Renton | Director | Sale plan | 5,000 | $49.87 | $249K | Form 4 |
| Mar 30, 2026 | John P. Schmid | Director | Sale | 12,596 | $55.71 | $702K | Form 4 |
| Mar 30, 2026 | John P. Schmid | Director | Sale | 7,527 | $56.70 | $427K | Form 4 |
| Mar 30, 2026 | John P. Schmid | Director | Sale | 522 | $57.40 | $30K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 100 | $65.99 | $6.6K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 3,038 | $65.20 | $198K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 3,155 | $64.19 | $203K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 2,592 | $63.35 | $164K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 1,012 | $62.15 | $62.9K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 550 | $60.63 | $33.3K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 490 | $59.62 | $29.2K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 3,662 | $58.62 | $215K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 510 | $56.61 | $28.9K | Form 4 |
| Mar 27, 2026 | Daniel Faga | CEO | Sale | 2,570 | $57.91 | $149K | Form 4 |
| Feb 11, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 10,000 | $54.00 | $540K | Form 4 |
| Jan 15, 2026 | Magda Marquet | Director | Sale | 9,290 | $48.12 | $447K | Form 4 |
| Jan 15, 2026 | Magda Marquet | Director | Sale | 1,710 | $48.85 | $83.5K | Form 4 |
| Jan 8, 2026 | Paul F. Lizzul | Chief Medical Officer | Sale | 3,650 | $44.71 | $163K | Form 4 |
| Jan 8, 2026 | Dennis Mulroy | CFO | Sale | 2,515 | $44.71 | $112K | Form 4 |
| Jan 8, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 2,210 | $44.71 | $98.8K | Form 4 |
| Jan 8, 2026 | Daniel Faga | CEO | Sale | 14,281 | $44.71 | $639K | Form 4 |
| Jan 7, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 2,017 | $45.11 | $91K | Form 4 |
| Jan 7, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 5,281 | $45.38 | $240K | Form 4 |
| Jan 7, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 500 | $47.23 | $23.6K | Form 4 |
| Jan 7, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 1,841 | $46.13 | $84.9K | Form 4 |
| Jan 7, 2026 | Paul F. Lizzul | Chief Medical Officer | Sale | 2,235 | $45.11 | $101K | Form 4 |
| Jan 7, 2026 | Daniel Faga | CEO | Sale | 9,202 | $45.11 | $415K | Form 4 |
| Jan 7, 2026 | Dennis Mulroy | CFO | Sale | 1,908 | $45.11 | $86.1K | Form 4 |
| Jan 5, 2026 | Daniel Faga | CEO | Sale | 15,309 | $43.26 | $662K | Form 4 |
| Jan 5, 2026 | Dennis Mulroy | CFO | Sale | 3,363 | $43.26 | $145K | Form 4 |
| Jan 5, 2026 | Paul F. Lizzul | Chief Medical Officer | Sale | 4,219 | $43.26 | $183K | Form 4 |
| Jan 5, 2026 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale | 2,983 | $43.26 | $129K | Form 4 |
| Dec 23, 2025 | J. Anthony Ware | Director | Sale | 3,900 | $49.58 | $193K | Form 4 |
| Dec 22, 2025 | Paul F. Lizzul | Chief Medical Officer | Sale plan | 1,500 | $50.00 | $75K | Form 4 |
| Dec 22, 2025 | Dennis Mulroy | CFO | Sale plan | 10,000 | $50.00 | $500K | Form 4 |
| Dec 22, 2025 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 10,000 | $51.00 | $510K | Form 4 |
| Dec 18, 2025 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 141 | $46.99 | $6.6K | Form 4 |
| Dec 17, 2025 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 10,000 | $46.00 | $460K | Form 4 |
| Dec 16, 2025 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 8,305 | $44.68 | $371K | Form 4 |
| Dec 16, 2025 | Eric J Loumeau | CHIEF LEGAL OFFICER | Sale plan | 4,195 | $45.24 | $190K | Form 4 |
| Dec 16, 2025 | Dennis Mulroy | CFO | Sale plan | 9,365 | $44.62 | $418K | Form 4 |
| Dec 16, 2025 | Dennis Mulroy | CFO | Sale plan | 6,360 | $45.21 | $288K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daniel Faga | President, CEO, Director | – | $2.8M | Mar 27, 2026 |
| Eric J Loumeau | CHIEF LEGAL OFFICER | – | $2.7M | Feb 11, 2026 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | – | $1.5M | Jan 8, 2026 |
| John P. Schmid | Director | – | $1.2M | Mar 30, 2026 |
| Magda Marquet | Director | – | $531K | Jan 15, 2026 |
| Paul F. Lizzul | Chief Medical Officer | – | $522K | Jan 8, 2026 |
| Hollings Renton | Director | – | $249K | Oct 1, 2026 |
| J. Anthony Ware | Director | – | $193K | Dec 23, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANAB short interest
High short interest. 16.9% of ANAB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 5%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.05M ANAB shares were sold short, 16.9% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 468,120 shares, buying them all back would take about 10.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.05M | 16.89% | -6% | 468,120 | 10.8 |
| Oct 15, 2026 | 5.39M | 18.04% | +3% | 507,972 | 10.6 |
| Sep 30, 2026 | 5.24M | 17.51% | -4% | 639,524 | 8.2 |
| Sep 15, 2026 | 5.44M | 18.68% | +0% | 530,306 | 10.2 |
| Aug 31, 2026 | 5.41M | 18.60% | +2% | 347,135 | 15.6 |
| Aug 14, 2026 | 5.32M | 18.27% | -2% | 372,089 | 14.3 |
| Jul 31, 2026 | 5.40M | 18.56% | +8% | 749,400 | 7.2 |
| Jul 15, 2026 | 5.00M | 17.18% | -3% | 853,496 | 5.9 |
| Jun 30, 2026 | 5.15M | 17.69% | +11% | 622,514 | 8.3 |
| Jun 15, 2026 | 4.63M | 15.92% | -4% | 566,928 | 8.2 |
| May 29, 2026 | 4.82M | 16.57% | +1% | 489,677 | 9.8 |
| May 15, 2026 | 4.80M | 16.48% | +8% | 660,958 | 7.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Anaptysbio company events
Anaptysbio filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Aug 11, 2026.
- Aug 11, 2026VoteReported shareholder vote results. Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jun 22, 2026AgreementAnaptysBio, Inc., entered into a Sublease Agreement with First Tracks Biotherapeutics, Inc., a Delaware corporation, pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121. Filing
- May 29, 2026AnnouncementShared information with investors. Filing
- May 21, 2026RulesChanged its bylaws or articles. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 11, 2026LeadershipAnaptysBio, Inc. announced that its Board of Directors appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026. Filing
- Apr 20, 2026LeadershipBoard Departures In connection with the Spin-Off, each of Dennis Fenton, Rita Jain and Magda Marquet resigned from the board of directors of the Company, effective as of April 20, 2026, and J. Anthony Ware resigned from the board of directors of the Company, effective as of April 23, 2026. Filing
- Mar 27, 2026LeadershipThe Board appointed Susannah Gray as a Class I director, a member of the Nominating and Corporate Governance Committee and a member of the Research and Development Committee, effective immediately. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Jan 9, 2026ResultsReleased financial results. Filing
- Nov 26, 2025AnnouncementShared information with investors. Filing
- Nov 21, 2025AnnouncementAnaptysBio, Inc. issued a press release announcing that its Board of Directors authorized an amendment to its Stock Repurchase Plan previously approved in March 2025, under which the Company may repurchase up to an additional $100.0 million of the Company’s outstanding common stock, par value… Filing
- Nov 21, 2025AnnouncementAnaptysBio, Inc. ( AnaptysBio ) filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. has materially breached the parties’ Collaboration and Exclusive License Agreement and that GlaxoSmithKline (“ GSK ” ), Tesaro’s corporate parent, has tortiously… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Anaptysbio financials
Famous investors that hold ANAB
4 of the 50 well-known investors we track reported holding ANAB in their latest 13F filing. The largest position is Israel Englander's, worth $39.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 784,560 | $39.4M | 0.0% | -3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 650,585 | $32.7M | 0.0% | +65% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 27,218 | $1.4M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 23,436 | $1.2M | 0.0% | +17% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ANAB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 3.1% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 3.1% |
Questions about Anaptysbio, Inc (ANAB) stock
Who owns the most ANAB stock?
The largest reported owner of Anaptysbio, Inc (ANAB) is EcoR1 Capital, LLC, with 27.1% of the company. In total, 211 funds and institutions reported holding ANAB at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ANAB insiders buying or selling?
In the last 12 months, ANAB insiders reported no open-market purchases and 42 sales worth $9.8M. The latest trade was on Oct 1, 2026. See every trade.
What is the short interest in ANAB?
As of Oct 30, 2026, 5.05M ANAB shares were sold short, 16.9% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 468,120 shares, buying them all back would take about 10.8 trading days (days to cover). See the history.
Which famous investors hold ANAB?
4 of the 50 well-known investors we track reported ANAB in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $39.4M. See all holders.
Executive pay
Anaptysbio's chief executive was paid a total of $6.1M for the year ended Dec 31, 2025, down 55% from $13.6M the year before. In the last 12 months, Anaptysbio's executives and directors bought no stock on the open market and sold $9.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.